Breaking News Instant updates and real-time market news.

CVS

CVS Health

$75.38

0.33 (0.44%)

, TGT

Target

$125.29

-0.61 (-0.48%)

08:10
12/02/19
12/02
08:10
12/02/19
08:10

CVS Pharmacy completes roll-out of time delay safes in North Carolina pharmacies

CVS Pharmacy, the retail division of CVS Health (CVS), announced that it has completed the roll-out of time delay safes in all of its 375 CVS Pharmacy locations in North Carolina, including pharmacies located in Target (TGT) stores. The safes are anticipated to help prevent pharmacy robberies and the diversion of controlled substance narcotic medications by keeping them out of the hands of unauthorized individuals. In addition, the safes are anticipated to help CVS Pharmacy ensure the safety and well-being of its customers and employees.

CVS

CVS Health

$75.38

0.33 (0.44%)

TGT

Target

$125.29

-0.61 (-0.48%)

CVS CVS Health
$75.38

0.33 (0.44%)

11/07/19
RHCO
11/07/19
NO CHANGE
Target $85
RHCO
Buy
CVS Health price target raised to $85 from $75 at SunTrust
SunTrust analyst David MacDonald raised his price target on CVS Health to $85 and kept his Buy rating after its Q3 earnings beat and raised FY19 guidance. The analyst says the quarter was highlighted by solid core trends, strong script growth, and robust free cash flows, along with progress in the integration synergies and cost savings from the Aetna merger.
11/07/19
RAJA
11/07/19
NO CHANGE
Target $80
RAJA
Strong Buy
CVS Health price target raised to $80 from $75 at Raymond James
Raymond James analyst John Ransom raised his price target for CVS Health to $80 from $75 and reiterated a Strong Buy rating after better than expected Q3 results and $8B in deleveraging since the Aetna deal closed, already nearly $1B higher than the annual estimate. Though the retail pharmacy and PBM markets may be facing headwinds the bar is low, Ransom tells investors in a research note that he thinks CVS is positioned so be a net winner, with the diversification of the payor business not reflected in current valuations.
11/08/19
MZHO
11/08/19
NO CHANGE
Target $82
MZHO
Buy
CVS Health price target raised to $82 from $71 at Mizuho
Mizuho analyst Ann Hynes raised her price target for CVS Health to $82 from $71 saying that for the third consecutive quarter, the company either met or beat estimates. She sees good execution and keeps a Buy rating on the shares.
11/18/19
RHCO
11/18/19
NO CHANGE
RHCO
Healthcare Services targets raised at SunTrust on visibility under Warren plans
SunTrust analyst David MacDonald raised his price targets on Anthem (ANTM) to $330 from $300, Cigna (CI) to $250 from $230, Centene (CNC) to $77 from $72, CVS (CVS) to $90 from $85, Humana (HUM) to $370 from $350, Molina Healthcare (MOH) to $165 from $155, Tivity Health (TVTY) to $25 from $21, UnitedHealth (UNH) to $335 from $310, and Wellcare (WCG) to $340 from $320. The analyst cites the release of Senator Warren's plans to implement "Medicare For All", which he believes offers additional clarity and allays some investor concerns regarding the sector. MacDonald contends that the plan will offer an early buy-in, comprehensive coverage that is similar to Medicare Advantage, while strengthening the ACA/Medicaid system and offering a transition period to move to Medicare For All. The analyst adds that Managed Care companies will remain a "key part of the healthcare cost solution".
TGT Target
$125.29

-0.61 (-0.48%)

11/21/19
KEYB
11/21/19
NO CHANGE
Target $140
KEYB
Overweight
Target price target raised to $140 from $130 at KeyBanc
KeyBanc analyst Edward Yruma raised his price target for Target to $140 from $130, saying Target's Q3 results affirm his thesis that it can take market share and grow margin due to favorable mix. Yruma tells investors in a research note that he thinks Target is uniquely positioned to take share and says Target is one of the best-positioned in his coverage. He keeps an Overweight rating on the shares.
11/21/19
RAJA
11/21/19
NO CHANGE
Target $150
RAJA
Strong Buy
Target price target raised to $150 from $130 at Raymond James
Raymond James analyst Matthew McClintock raised his price target for Target (TGT) to $150 from $130 and maintained a Strong Buy rating following the company's Q3 results, saying this quarter will likely force many investors to re-evaluate their longer-term view of the Target story. He also expects investors to increasingly use the current valuation of Walmart (WMT) as a potential upside case for Target, particularly given Target's "superior" underlying metrics.
11/21/19
BUCK
11/21/19
NO CHANGE
Target $145
BUCK
Buy
Target price target raised to $145 from $131 at Buckingham
Buckingham analyst Bob Summers raised his price target for Target to $145 from $131 and reiterated a Buy rating following the company's Q3 results, saying he remains constructive on the shares and expects the stock to further re-rate higher. In a research note to investors, Summers says the company is poised to continue to gain market share and sustain current operating momentum with respect to both sales and margins and should be viewed as a winner in the shifting retail landscape, and feels ongoing initiatives like branded partnerships will drive growth and improvement over the foreseeable future and create the prospect of further valuation expansion augmented by an upward bias to earnings estimates.
11/29/19
RAJA
11/29/19
NO CHANGE
RAJA
Holiday shopping season appears to have started out strong, says Raymond James
Raymond James analyst Matthew McClintock said his checks on Thursday evening indicate that physical store traffic was strong at both Best Buy (BBY) and Target (TGT), which he thinks "should be viewed as even more impressive than initial indications that e-commerce sales have been stronger than expected." He also noted that some retailers had such strong e-commerce traffic that website performance suffered, listing Facebook (FB), Nordstrom (JWN) and Costco (COST) as some examples. The Fly notes that the S&P Retail Index SPDR (XRT) may react today to headlines regarding checks on retail spending on Thanksgiving and Black Friday.

TODAY'S FREE FLY STORIES

PLMR

Palomar

20:27
12/08/19
12/08
20:27
12/08/19
20:27
Recommendations
Palomar analyst commentary at Keefe Bruyette »

Palomar price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

ASAZY

Assa Abloy

$0.00

(0.00%)

20:23
12/08/19
12/08
20:23
12/08/19
20:23
Downgrade
Assa Abloy rating change at JPMorgan »

Assa Abloy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RXEEY

Rexel

$0.00

(0.00%)

20:23
12/08/19
12/08
20:23
12/08/19
20:23
Upgrade
Rexel rating change at JPMorgan »

Rexel upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TATYY

Tate & Lyle

$0.00

(0.00%)

20:22
12/08/19
12/08
20:22
12/08/19
20:22
Upgrade
Tate & Lyle rating change at Jefferies »

Tate & Lyle upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUO

AU Optronics

$0.00

(0.00%)

20:20
12/08/19
12/08
20:20
12/08/19
20:20
Upgrade
AU Optronics rating change at Morgan Stanley »

AU Optronics upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPL

LG Display

$6.22

0.115 (1.89%)

20:17
12/08/19
12/08
20:17
12/08/19
20:17
Upgrade
LG Display rating change at Morgan Stanley »

LG Display upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

ETNB

89bio

$28.38

0.86 (3.13%)

20:16
12/08/19
12/08
20:16
12/08/19
20:16
Initiation
89bio initiated at Oppenheimer »

89bio initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANIOY

Acerinox

$0.00

(0.00%)

20:15
12/08/19
12/08
20:15
12/08/19
20:15
Upgrade
Acerinox rating change at Jefferies »

Acerinox upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BPMC

Blueprint Medicines

$78.50

3.92 (5.26%)

20:15
12/08/19
12/08
20:15
12/08/19
20:15
Conference/Events
Blueprint Medicines to hold an anlayst and investor event »

Management reviews the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 08

    Dec

TLSNY

Telia

$0.00

(0.00%)

20:14
12/08/19
12/08
20:14
12/08/19
20:14
Downgrade
Telia rating change at Jefferies »

Telia downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARWR

Arrowhead

$67.25

1.705 (2.60%)

20:13
12/08/19
12/08
20:13
12/08/19
20:13
Recommendations
Arrowhead analyst commentary at Piper Jaffray »

Arrowhead price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARGX

Argenx

$147.31

-2.56 (-1.71%)

20:08
12/08/19
12/08
20:08
12/08/19
20:08
Recommendations
Argenx analyst commentary at Stifel »

Argenx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

STC

Stewart

$43.16

0.28 (0.65%)

19:56
12/08/19
12/08
19:56
12/08/19
19:56
Downgrade
Stewart rating change at Keefe Bruyette »

Stewart downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FAF

First American

$63.05

(0.00%)

19:55
12/08/19
12/08
19:55
12/08/19
19:55
Downgrade
First American rating change at Keefe Bruyette »

First American downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

PFSI

PennyMac Financial

$33.91

0.12 (0.36%)

19:54
12/08/19
12/08
19:54
12/08/19
19:54
Downgrade
PennyMac Financial rating change at Keefe Bruyette »

PennyMac downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGIO

Agios Pharmaceuticals

$40.93

0.81 (2.02%)

18:40
12/08/19
12/08
18:40
12/08/19
18:40
Recommendations
Agios Pharmaceuticals analyst commentary at Piper Jaffray »

Agios' initial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 13

    Dec

BPMC

Blueprint Medicines

$78.50

3.92 (5.26%)

18:34
12/08/19
12/08
18:34
12/08/19
18:34
Recommendations
Blueprint Medicines analyst commentary at Piper Jaffray »

Piper says 'jury…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 08

    Dec

FATE

Fate Therapeutics

$13.64

0.07 (0.52%)

18:29
12/08/19
12/08
18:29
12/08/19
18:29
Recommendations
Fate Therapeutics analyst commentary at Piper Jaffray »

FT500 data validates Fate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCKT

Rocket Pharmaceuticals

$22.37

2.61 (13.21%)

18:05
12/08/19
12/08
18:05
12/08/19
18:05
Hot Stocks
Rocket says Phase 1 trial establishes feasibility of commercial Process B for FA »

Rocket Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 08

    Dec

ARGX

Argenx

$147.31

-2.56 (-1.71%)

, JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

18:03
12/08/19
12/08
18:03
12/08/19
18:03
Recommendations
Argenx, Johnson & Johnson analyst commentary at Piper Jaffray »

Argenx data on…

ARGX

Argenx

$147.31

-2.56 (-1.71%)

JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

  • 16

    Dec

  • 21

    Jan

BLUE

Bluebird Bio

$79.51

-1.24 (-1.54%)

, JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

17:58
12/08/19
12/08
17:58
12/08/19
17:58
Recommendations
Bluebird Bio, Johnson & Johnson, Amgen, Bristol-Myers, Regeneron analyst commentary at Piper Jaffray »

Piper says…

BLUE

Bluebird Bio

$79.51

-1.24 (-1.54%)

JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

AMGN

Amgen

$233.74

0.3 (0.13%)

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

REGN

Regeneron

$372.26

4.02 (1.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

  • 21

    Jan

BGNE

BeiGene

$186.89

-2.3 (-1.22%)

17:50
12/08/19
12/08
17:50
12/08/19
17:50
Hot Stocks
BeiGene announces data from two clinical trials of Brukinsa at ASH meeting »

BeiGene announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 27

    Feb

LLY

Eli Lilly

$119.59

-0.175 (-0.15%)

16:34
12/08/19
12/08
16:34
12/08/19
16:34
Hot Stocks
Eli Lilly presents interim clinical data from LOXO-305 dose escalation trial »

Eli Lilly announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

  • 17

    Dec

  • 30

    Jan

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

16:32
12/08/19
12/08
16:32
12/08/19
16:32
Hot Stocks
Bristol-Myers announces data from multiple liso-cel studies at ASH meeting »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

QURE

uniQure

$66.06

1.5 (2.32%)

16:26
12/08/19
12/08
16:26
12/08/19
16:26
Hot Stocks
uniQure reports 1-year follow-up data from etranacogene dezaparvovec study »

uniQure announced updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.